XOMA Announces Phase 3 EYEGUARD(TM)-B Study Reaches Target Exacerbation Event May 28, 2015 8:30am EDT
Servier Initiates Phase 2 Study of Gevokizumab in Patients With Diabetic Nephropathy Apr 01, 2015 8:01am EDT
XOMA Highlights Recent Achievements and Reports Fourth Quarter and Full-Year 2014 Financial Results Mar 11, 2015 4:01pm EDT
XOMA Announces Retirement of Fred Kurland and Appointment of Thomas Burns as Chief Financial Officer Mar 03, 2015 7:00am EST
XOMA to Announce Fourth Quarter and Full Year 2014 Financial Results and Host Webcast on March 11 Feb 26, 2015 3:22pm EST
